MOTGNN: Interpretable Graph Neural Networks for Multi-Omics Disease Classification Conference: ; ;
Tiantian Yang, Zhiqian Chen · 2025
Read MOTGNN: Interpretable Graph Neural Networks for Multi-Omics Disease Classification Conference: ; ; by Tiantian Yang, Zhiqian Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2508-07465.txt.
Introduction
Tiantian Yang and Zhiqian Chen present MOTGNN in a 2025 paper on sorting disease from multi-omics data. Such data join gene activity, gene marks, and small RNA levels for a full view of an illness. The sets are huge, mixed in kind, and hard to join without known gene links.
Their frame builds a graph for each data type with a boosting method, then learns from each graph with its own network. A final network joins the three views to class each case. Tests on three real disease sets beat past methods and stayed strong when classes were lopsided, while naming top markers.
Catalog record
| CREATOR | Tiantian Yang, Zhiqian Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2508-07465
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
MOTGNN: Interpretable Graph Neural Networks for Multi-Omics Disease Classification Conference: ; ; Tiantian Yang, Zhiqian Chen Abstract . Integrating multi-omics data, such as DNA methylation, mRNA expression, and microRNA (miRNA) expression, offers a comprehensive view of the biological mechanisms underlying disease. However, the high dimensionality and complex interactions among omics layers present major challenges for predictive modeling. We propose Multi-Omics integration with Tree-generated Graph Neural Network ( MOTGNN ), a novel and interpretable framework for binary disease classification. MOTGNN employs eXtreme Gradient Boosting (XGBoost) to perform omics-specific supervised graph construction, followed by modality-specific Graph Neural Networks (GNNs) for hierarchical representation learning, and a deep feedforward network for cross-omics integration. On three real-world disease datasets, MOTGNN outperforms state-of-the-art baselines by 5-10% in accuracy, ROC-AUC, and F1-score, and remains robust to severe class imbalance (e.g., 87.2% vs. 33.4% F1 on imbalanced data). The model maintains computational efficiency through sparse graphs (2.1-2.8 edges per node) and provides built-in interpretability, revealing both top-ranked biomarkers and the relative contributions of each omics modality. These results highlight MOTGNN’s potential to improve both predictive accuracy and interpretability in multi-omics disease modeling. 1. Introduction A comprehensive understanding of complex diseases, such as cancer, cardiovascular disease, and neurodegenerative disorders, is critical for advancing public health and enabling precision medicine. These diseases are not driven by isolated molecular events but emerge from intricate interactions among genomic, epigenomic, and transcriptomic factors ( Subramanian et al. 2020 ) . Recent advances in high-throughput biotechnologies have enabled the simultaneous collection of different layers of molecular regulation, such as gene expression (messenger RNA), epigenetic modifications (DNA methylation), and non-coding RNA activity (e.g., microRNA), from the same set of biological samples ( Hood and Rowen 2013 ) . These omics datasets capture intricate relationships among biological entities and molecular processes, offering insights into disease mechanisms. While individual omics types provide valuable information, different modalities reflect distinct biological processes and contribute complementary information. Integrating multiple omics (multi-omics) data is essential to comprehensively understand the complex, multi-layered systems underlying disease processes and their progression ( Waqas et al. 2024 ) . However, integrating heterogeneous omics data presents unique challenges. A fundamental issue is that the number of samples ( n ) is substantially smaller than the number of features ( p ). For example, a study may involve only a few hundred participants while measuring tens of thousands of molecular features. This high dimensionality complicates learning and increases the risk of overfitting. Moreover, not all measured features are biologically relevant; noisy or redundant features can obscure meaningful patterns. Although prior biological knowledge, such as gene-gene or protein-protein interactions, has been identified experimentally, our knowledge is constrained by experimental design and equipment constraints. Consequently, there is a growing need for computational models that can reliably infer biologically meaningful structures and interactions from multi-omics data ( Jiang et al. 2025 ) . Traditional machine learning and deep learning models have been extensively applied to address the high dimensionality and complexity of omics data ( Ayman et al. 2023 ; Zaghlool and Attallah 2022 ) , but most of these approaches assume a Euclidean data structure. Classical machine learning methods, such as random forests ( Breiman 2001 ) and gradient boosting methods, such as XGBoost ( Chen and Guestrin 2016 ) , operate by constructing ensembles of decision trees and are effective for classification tasks, but they typically treat features as independent and fail to capture structural relationships among them. Deep learning models ( Lecun et al. 2015 ) , such as deep feedforward networks (DFNs) ( Goodfellow et al. 2016 ) , convolutional neural networks, and recurrent neural networks, can model nonlinear feature dependencies but are not designed to process non-Euclidean data structures such as graphs. These approaches typically require large training sets to avoid overfitting. Moreover, their black-box nature often limits interpretability, which is essential in biomedical applications where transparency and reproducibility are critical. Furthermore, concatenating features from different omics modalities as input can obscure modality-specific relationships and introduce additional noise. Graph-based approaches offer a natural alternative for modeling complex biological systems. In omics applications, nodes can represent features (e.g., genes) or samples, and edges encode various relationships, such as similarity, co-expression, or learned interactions. Graph Neural Networks (GNNs) ( Bronstein et al. 2017 ; Wu et al. 2020 ; Zhang et al. 2020 ; Zhou et al. 2020 ; Chen et al. 2023 ) have emerged as powerful tools for learning from graph-structured data by recursively aggregating information from each node’s neighborhood. GNNs capture both local and global graph topology and have found increasing use in biomedical applications, including molecular modeling, medical imaging, drug discovery, and disease prediction ( Zhang et al. 2021 ; Johnson et al. 2024 ; Waqas et al. 2024 ; Zhong et al. 2025 ) . Foundational models such as message passing neural networks (MPNNs) ( Gilmer et al. 2017 ) , graph convolutional networks (GCNs) ( Kipf and Welling 2017 ) , graph attention networks (GATs) ( Petar et al. 2018 ) , GraphSAGE ( Hamilton et al. 2017 ) , and graph isomorphism networks (GINs) ( Xu et al. 2019 ) have significantly advanced the expressiveness and scalability of GNN-based learning. Despite recent advances, applying GNNs to multi-omics data remains challenging and relatively underexplored ( Zhang et al. 2021 ; Valous et al. 2024 ; Paul et al. 2024 ; Ballard et al. 2024 ) . The irregular nature of graph-structured data further complicates this task, as each node may have a variable number of neighbors, and many standard deep learning operations are not directly applicable in this setting ( Chen et al. 2023 ) . Although several GNN-based frameworks have been proposed for multi-omics integration, many of these works exhibit substantial limitations, which we summarize into three main areas: (1) Inadequate modeling of high-dimensional, heterogeneous omics data : To address high dimensionality (i.e., the “small n , large p ” issue), existing methods typically apply simple filtering techniques, such as removing low-variance or zero-valued features, or selecting features based on univariate statistical tests. Some approaches flatten multi-omics data by concatenating omics layers before graph construction, which weakens modality-specific signals and ignores biological heterogeneity. Others rely heavily on hand-crafted similarity graphs (e.g., Pearson or cosine similarity), which may miss nonlinear, task-specific relationships, ignore the sparse and scale-free nature of biological graphs, and are sensitive to arbitrary thresholding or preprocessing pipelines. (2) Vulnerability to class imbalance : While class imbalance is prevalent in biomedical datasets (e.g., rare diseases, early-stage cancer detections, or minority subtypes), it is rarely addressed during model development or evaluation. Many existing models optimize for overall accuracy, which can be misleading when predictions favor the majority class. In these scenarios, even high accuracy may reflect poor minority class detection. As a result, these approaches often lack robustness and generalizability in imbalanced settings, where accurate prediction of minority cases is of greater biological and clinical importance. (3) Limited interpretability and biological insight : Interpretability is essential in biomedical research, as understanding which features or omics modalities drive predictions is essential for trust, transparency, and downstream biological discovery. However, most existing GNN-based models lack built-in interpretability. Instead, they rely on computationally intensive post hoc analyses or ablation studies to infer importance,